Gemphire Therapeutics Inc.
(NASDAQ : GEMP)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
0.78%36.000.8%$762.28m
JNJJohnson & Johnson
0.38%123.380.6%$756.96m
ABBVAbbVie, Inc.
-0.57%105.632.1%$745.40m
MRKMerck & Co., Inc.
1.32%59.220.6%$602.57m
BMYBristol-Myers Squibb Company
0.50%52.601.4%$457.22m
LLYEli Lilly and Company
0.63%82.741.0%$343.93m
AZNAstraZeneca PLC Sponsored ADR
-0.68%36.801.3%$160.72m
NVSNovartis AG Sponsored ADR
-0.52%76.440.2%$109.80m
GSKGlaxoSmithKline plc Sponsored ADR
-0.34%40.200.2%$109.43m
NVONovo Nordisk A/S Sponsored ADR Class B
-0.75%48.260.1%$74.48m
SNYSanofi Sponsored ADR
-1.02%38.540.2%$42.93m
LCILannett Company, Inc.
1.49%17.0037.9%$13.65m
EPIXESSA Pharma Inc
1.83%3.340.0%$0.17m
AKTXAkari Therapeutics Plc Sponsored ADR
-1.57%1.881.7%$0.12m

Company Profile

Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of treatment options for cardiometabolic diseases including dyslipidemia and NASH. Its product name is Gemcabene, a small molecule formulated as a tablet . The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Northville, MI.